 NEW YORK, Oct. 1, 2021 PRNewswire -- BrainStorm Cell Therapeutics Inc. NASDAQ: BCLI, a leading developer of cellular therapies for neurodegenerative diseases, announced today that a scientific abstract titled Phase 2 Safety and Efficacy Study of Intrathecal MSC-NTF cells in Progressive Multiple Sclerosis will be presented in an oral presentation at the fully digital 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS. The presentation will be delivered by Jeffrey Cohen, M.D. 